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Effect of Achilles Tendon 
Lengthening on 
Neuropathic Plantar Ulcers*
A RANDOMIZED CLINICAL TRIAL
BY MICHAEL J. MUELLER, PT, PHD, DAVID R. SINACORE, PT, PHD, MARY KENT HASTINGS, MS/PT, ATC, 
MICHAEL J STRUBE, PHD, AND JEFFREY E. JOHNSON, MD
Investigation performed at the Washington University School of Medicine, St. Louis, Missouri
Background: Limited ankle dorsiflexion has been implicated as a contributing factor to plantar ulceration of the fore-
foot in diabetes mellitus. The purpose of this study was to compare outcomes for patients with diabetes mellitus and
a neuropathic plantar ulcer treated with a total-contact cast with and without an Achilles tendon lengthening. Our pri-
mary hypothesis was that the Achilles tendon lengthening would lead to a lower rate of ulcer recurrence.
Methods: Sixty-four subjects were randomized into two treatment groups, immobilization in a total-contact cast alone or
combined with percutaneous Achilles tendon lengthening, with measurements made before and after treatment, at the
seven-month follow-up examination, and at the final follow-up evaluation (a mean [and standard deviation] of 2.1 ± 0.7
years after initial healing). There were thirty-three subjects in the total-contact cast group and thirty-one subjects in the
Achilles tendon lengthening group. There were no significant differences in age, body-mass index, or duration of diabe-
tes between the groups. Outcome measures were time to healing of the ulcer, ulcer recurrence rate, range of dorsiflex-
ion of the ankle, peak torque (strength) of the plantar flexor muscles, and peak plantar pressures on the forefoot.
Results: Twenty-nine (88%) of thirty-three ulcers in the total-contact cast group and all thirty ulcers (100%) in the Achil-
les tendon lengthening group healed after a mean duration (and standard deviation) of 41 ± 28 days and 58 ± 47 days,
respectively (p > 0.05). (One patient in the Achilles tendon lengthening group died before treatment was completed.) In
the first seven months of follow-up, sixteen (59%) of the twenty-seven patients in the total-contact cast group who were
available for follow-up and four (15%) of the twenty-seven patients in the Achilles tendon lengthening group who were
available for follow-up had an ulcer recurrence (p = 0.001). At the time of the two-year follow-up, twenty-one (81%) of the
twenty-six patients in the total-contact cast group and ten (38%) of the twenty-six patients in the Achilles tendon length-
ening group had ulcer recurrence (p = 0.002). Compared with the group treated with the total-contact cast, the group
treated with Achilles tendon lengthening had increased dorsiflexion and it remained increased at seven months (p <
0.001). Plantar flexor peak torque also decreased after Achilles tendon lengthening (p < 0.004), but it returned to base-
line after seven months. Peak plantar pressures on the forefoot during barefoot walking were reduced (p < 0.0002) fol-
lowing Achilles tendon lengthening yet returned to baseline values within seven months after treatment.
Conclusions: All ulcers healed in the Achilles tendon lengthening group, and the risk for ulcer recurrence was 75%
less at seven months and 52% less at two years than that in the total-contact cast group. Achilles tendon lengthening
should be considered an effective strategy to reduce recurrence of neuropathic ulceration of the plantar aspect of the
forefoot in patients with diabetes mellitus and limited ankle dorsiflexion (≤5°).
Level of Evidence: Therapeutic study, Level I-1a (randomized controlled trial [significant difference]). See Instruc-
tions to Authors for a complete description of levels of evidence.
lantar ulcers in diabetic patients are commonly caused
by high plantar pressures in the presence of sensory
neuropathy and foot deformity1,2. Most foot ulcers (ap-
proximately 75%) occur beneath the metatarsal heads and are
the result of painless trauma caused by excessive plantar pres-
sures during normal walking1,3. Limited dorsiflexion of the
foot on the leg, which is thought to occur primarily at the an-
kle joint (i.e., equinus deformity)4-8, has been implicated as a
contributing factor to excessive plantar pressures and forefoot
skin breakdown. Limited ankle dorsiflexion presumably re-
P
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stricts the leg from rolling over the foot during the late stance
phase of walking and places excessive pressure on the plantar
aspect of the forefoot, contributing to recurrent skin break-
down and delayed wound-healing.
Immobilization in a total-contact cast is an effective am-
bulatory method to heal plantar ulcers in patients with diabe-
tes mellitus. Numerous descriptive studies3,9,10 and controlled
clinical trials11,12 have provided evidence that approximately
90% of these neuropathic plantar wounds heal after an aver-
age duration of six weeks. Treatment with a total-contact cast
appears to be effective, in part, because it reduces the plantar
pressures at the ulcer site13,14. Despite the documented ability
of a total-contact cast to heal primary ulcers, the ulcer recur-
rence rate is high, ranging from 20% to 70%15-17. The time-
period associated with the greatest likelihood of reulceration
(a rate of 20% to 57%) is thought to be within the first month
after the patient resumes walking without the cast17,18.
A number of investigators have proposed that patients
with recurrent ulceration and limited ankle dorsiflexion
should have an Achilles tendon lengthening to increase mo-
tion, reduce stress on the forefoot, and help to prevent skin
breakdown5-8. Descriptive studies have noted an increase of 9°
to 18° of ankle dorsiflexion following surgery6-8. Armstrong et
al. reported that the mean peak pressure (and standard devia-
tion) on the forefoot decreased from 86 ± 9 N/cm2 to 63 ± 13
N/cm2 at eight weeks after an Achilles tendon lengthening in
ten patients with diabetes mellitus7. Furthermore, Lin et al. re-
ported that none of fifteen patients managed with an Achilles
tendon lengthening had an ulcer recurrence after more than
seventeen months of follow-up6.
An Achilles tendon lengthening presumably changes the
length-tension relationship in the gastrocnemius and soleus
muscles and likely affects muscle performance. We could find
few clinical data to indicate the effect of Achilles tendon length-
ening on muscle performance. While two computer simulation
studies of Achilles tendon lengthening for the treatment of
equinus deformity predicted substantial weakness in the plan-
tar flexor muscles19,20, no controlled clinical trials have been
conducted, as far as we know, to determine the effect of Achil-
les tendon lengthening on ulcer-healing, ankle dorsiflexion, or
performance of the plantar flexor muscles.
The primary purpose of this study was to compare the
effect of Achilles tendon lengthening followed by immobiliza-
tion in a total-contact cast with treatment with a total-contact
cast alone on the rate and duration of ulcer-healing and the
number of ulcer recurrences in the first two years of follow-
up. Secondary outcome measures were ankle dorsiflexion,
plantar flexor muscle strength, and peak plantar pressures on
the forefoot and the heel. Since use of a total-contact cast is an
effective treatment for healing ulcers, we did not expect a dif-
ference between the groups with respect to the duration of
healing but did expect a lower rate of ulcer recurrence in the
Achilles tendon lengthening group. Furthermore, we hypothe-
sized that ankle dorsiflexion would increase and peak plantar
pressures on the forefoot during walking would decrease in
the Achilles tendon lengthening group and would remain de-
creased over a seven-month follow-up period, whereas plantar
flexor muscle strength would decline after surgery but return
to baseline after seven months.
Materials and Methods
Study Design Overview
atients were randomly assigned to participate in one of
two treatment groups: Achilles tendon lengthening fol-
lowed by immobilization in a total-contact cast or immobili-
zation in a total-contact cast alone. Tests were conducted on
three occasions. The first test occurred at a mean (and stan-
dard deviation) of 9.8 ± 15.8 days before treatment; the second
test, or posttreatment test, at a mean of 17.3 ± 29.3 days after
termination of the primary treatment and healing of the plan-
tar ulcer; and the third test, at a mean of 7.1 ± 1.8 months after
initial ulcer-healing. A seven-month follow-up was chosen be-
cause we speculated that the plantar flexor muscles would
have had an adequate time to rehabilitate, and we could care-
fully monitor the time-period when ulcers are most likely to
recur. Patients were contacted by telephone every month to
question them about their health status and foot condition.
Patients who reported a reulceration were seen in the clinic.
We conducted a final follow-up telephone interview of all pa-
tients at an average of 2.1 ± 0.7 years after initial healing to as-
sess for recurrence of ulcers (Fig. 1). Special precautions were
not taken to blind the testers to the subject treatment group.
Inclusion Criteria
Patients were considered for inclusion in the study if they had a
history of diabetes mellitus, loss of protective sensation (unable
to sense the 5.07 Semmes-Weinstein monofilament on at least
one location on the plantar aspect of the foot), limitation of an-
kle dorsiflexion to ≤5°, a palpable ankle pulse, and a recurrent
or nonhealing ulcer on the forefoot (Grade II according to the
Wagner scale21). A limitation of 5° of ankle dorsiflexion was
chosen because most authors believe that ≥10° is required for
normal walking ability22. A recurrent or nonhealing ulcer was
defined as two or more occurrences of a plantar ulcer or the fail-
ure of a plantar ulcer to heal with conservative treatment (i.e.,
dressing changes and footwear modifications).
Exclusion Criteria
Patients were excluded from the study if they had a neurologi-
cal problem complicating the rehabilitation, had a history of
Charcot fractures of the hindfoot, were unable to tolerate the
anesthesia required for Achilles tendon lengthening, or if it
was thought that they would not benefit from an Achilles ten-
don lengthening (i.e., they were not able to walk). We did not
exclude individuals with a Charcot deformity of the midfoot
or forefoot or a partial foot amputation if they met the above
inclusion criteria.
Randomization
Randomization began in 1998 and was terminated in 2002. An
a priori power analysis was conducted to predict the number
of subjects needed for the primary and secondary measures.
P
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On the basis of a summary of ulcer recurrence rates ranging
from 9% to 57% following treatment with a total-contact
cast17 and a 0% recurrence rate following Achilles tendon
lengthening in one descriptive study6, a 25% effect size (the
percentage difference in success) was used for the power anal-
ysis. The power calculations assumed a minimum power of
0.80 and a significance level of 0.05, and they predicted that
100 patients would be required to identify group differences in
the rate of ulcer recurrence23. Next, a power analysis was con-
ducted for the secondary outcome measures (i.e., ankle dor-
siflexion, performance of the plantar flexor muscles, and
plantar pressures). Effect size was estimated conservatively at
50% of outcome variance accounted for by treatment group
differences6,7. We also assumed that other variables in the sta-
tistical model would account for ≥25% of the variance in out-
come. A sample size of sixty patients would allow detection of
a 25% effect size with power of 0.80 and an alpha level at 0.05
for the secondary outcome measures24. Because of the ex-
Fig. 1
Subject flow through the study. 
ATL = Achilles tendon lengthen-
ing, and TCC = total-contact cast.
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pected effect size, additional testing and cost to the project,
and inconvenience for the subjects (time and travel to a differ-
ent laboratory), only a subsample of subjects was tested for
secondary outcome measures. Finally, since the effect size of
intervention was greater than anticipated for all outcome
measures, testing was terminated in 2002 with the number of
subjects described in this study.
Subjects were recruited from the Diabetic Foot Center at
Barnes-Jewish Hospital associated with Washington Univer-
sity School of Medicine, St. Louis, Missouri. Informed consent
was obtained, with use of a form approved by the institutional
review board, from all subjects who agreed to participate.
Subjects were randomized into the Achilles tendon lengthen-
ing group or the total-contact cast group with use of a prear-
ranged schedule generated by a computer program. Because
we anticipated a much higher rate of reulceration in the total-
contact cast group compared with that in the Achilles tendon
lengthening group6, and we wanted subjects to have the op-
portunity to cross over to the Achilles tendon lengthening
group if treatment with a total-contact cast alone was not suc-
cessful, the prearranged schedule was planned to enroll two
times as many subjects in the total-contact cast group as in the
Achilles tendon lengthening group. Subjects who had a reul-
ceration after treatment with a total-contact cast were then al-
lowed to enter the Achilles tendon lengthening group. Subjects
who had a reulceration in the Achilles tendon lengthening
group could enter the total-contact cast group only if they
lacked 5° of ankle dorsiflexion, a criterion that they were un-
likely to meet. The orthopaedic surgeon (J.E.J.), who screened
all patients for eligibility into the study, was blind to the prear-
ranged schedule. Once the subject agreed to participate, he or
she was referred to the patient coordinator for the study who
assigned the subject to a treatment group according to the
prearranged schedule and arranged all testing sessions.
Subject Characteristics
Sixty-four subjects met the study criteria and agreed to partic-
ipate. Thirty-one subjects were randomly assigned to the
Achilles tendon lengthening group, and thirty-three subjects
were randomly assigned to the total-contact cast group (Fig.
1). Randomization methods were successful as there were no
differences between the groups with respect to any subject
characteristic (p > 0.05). Overall, the subjects had a mean age
(and standard deviation) of 56 ± 10 years, and they were pre-
dominantly male (forty-nine men and fifteen women) and
obese (mean body-mass index, 31.9 ± 7.3 kg). They usually
had Type-2 diabetes mellitus (forty-eight had Type 2 and six-
teen had Type 1), the mean duration of the diabetes was 18.4 ±
11.7 years, and the subjects had relatively poor glycemic con-
trol (mean HbA1c [glycated hemoglobin], 8.8% ± 1.8%) (Ta-
ble I). The patients presented with an average of 3.7 ± 4.0
previous ulcers. Methods of sensory testing followed a previ-
ously described reliable technique4,25. All subjects had severe
peripheral neuropathy and lacked protective sensation as evi-
denced by a history of a plantar ulcer and the inability to sense
the 5.07 Semmes-Weinstein monofilament on at least one lo-
cation on the plantar aspect of the foot25. Table II contains a
description of the foot deformities and comorbidities. There
were no differences between groups (p > 0.05) for any of these
characteristics.
Methods of Treatment
All necrotic tissue and callus surrounding the ulcer were sharply
débrided. The ulcer was covered with a dry gauze dressing. The
subjects who were randomized to the Achilles tendon lengthen-
ing group were placed supine on the operating table, and intra-
venous sedation was administered. After sterile preparation,
local anesthesia was injected along the subcutaneous border of
the Achilles tendon as a field block. Three hemisections were
made in the Achilles tendon with use of the Hoke triple he-
misection technique26. Then the surgeon firmly pushed on the
plantar aspect of the forefoot, dorsiflexing the ankle in a con-
trolled manner to allow the Achilles tendon to lengthen along
the course of its weakened fibers until the foot could be brought
Fig. 2
The Kaplan-Meier survivor probability 
curve for each group. The curves sepa-
rately indicate the probability of remaining 
ulcer-free over time. The subjects in the 
total-contact cast group (TCC) were much 
more likely to have an ulcer recurrence 
than were those in the Achilles tendon 
lengthening group (ATL), especially in the 
first weeks after initial healing. Day 0 indi-
cates initial healing of the ulcer.
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into 10° of dorsiflexion. Excessive force that might cause com-
plete transection or overlengthening of the tendon was carefully
avoided. No sutures were used to close the three tenotomy sites,
and a dry gauze dressing (4 by 4 in [10 by 10 cm]) was applied
and held in place with a sterile cotton wrap.
After the Achilles tendon lengthening, a total-contact
cast was applied as described previously27, except that the dis-
tal end of the toe box was left open and a standard rocker cast
shoe was used rather than a walking heel. The cast was applied
to the leg with the ankle joint in a neutral position. The cast
was initially changed after one week and was subsequently
changed every two to three weeks for at least six weeks or until
the forefoot ulcer had completely healed. The patient was al-
lowed partial weight-bearing immediately after application of
the total-contact cast and progressed to full weight-bearing af-
ter the first week but was asked to limit his or her activities as
much as possible. After application of the cast, the involved
foot was placed in a padded diabetic pressure-relief walking
boot (DH Pressure Relief Walker; Royce Medical, Camarillo,
California) for one to four weeks until the subject felt stable
enough to walk with the extra-depth shoes with custom-
molded inserts that were prescribed according to published
recommendations28.
Subjects who were randomly assigned to the total-contact
cast group were treated with a total-contact cast with use of
methods identical to those used in the Achilles tendon length-
ening group except that the patients were allowed full weight-
bearing immediately after the initial application of the cast.
The ankle was positioned as close to neutral as possible, and
the cast was changed every two to three weeks until the plantar
ulcer was healed. Subjects then were instructed to wear the ex-
tra-depth shoes with custom-molded inserts28.
After treatment, all subjects were instructed in a home-
exercise program by a physical therapist with use of a Thera-
Band (Hygenic, Akron, Ohio) to provide resistance to the
musculature around the ankle. The exercise program included
use of a red Thera-Band, progressing to a green one to resist
ankle plantar flexion, dorsiflexion, inversion, and eversion
movements. Exercises were completed in three sets with ten
repetitions in each set, one time per day, for three, four, or five
days per week29.
Primary Outcome Measures
The primary intent of the Achilles tendon lengthening is to
decrease the rate of ulcer recurrence. Therefore, primary out-
come measures were related to ulcer-healing. Ulcers were con-
sidered healed when they showed complete epithelialization
with no drainage. Ulcers were evaluated in each group every
seven to fourteen days by the physician as the casts were
changed. Ulcer-healing (yes or no) and the time to healing
(days) were recorded for each subject. Subjects were consid-
ered to have an ulcer recurrence if the ulcer reopened (a break
in epithelial tissue and drainage) in any location on the fore-
foot. If the subjects noticed any skin breakdown, they were in-
structed to contact the patient coordinator to schedule an
appointment in the clinic. Subjects also were contacted by
telephone every month for the first seven months after the
treatment and were asked about their health status and foot
condition, including the incidence of skin breakdown. At-
tempts also were made to contact all subjects by telephone for
a final follow-up evaluation regarding ulcer recurrence in
2002. Ulcer recurrence (yes or no) and, for those who had
ulcer recurrence, the time (days) from initial ulcer-healing to
ulcer recurrence were recorded.
TABLE I Subject Characteristics 
Group Treated with 
Achilles Tendon Lengthening 
Group Treated with 
Total-Contact Cast Alone
Age* (yr) 56.6 ± 9.2 56.2 ± 10.1
No. of patients 31 33
Male/female† 26/5 23/10
Type-1/type-2 diabetes mellitus (no. of patients) 5/26 11/22
Duration of diabetes mellitus* (yr) 17.1 ± 10.8 19.6 ± 12.6
Body-mass index* 33.3 ± 7.8 30.5 ± 6.8
HbA1c*† (%) 8.8 ± 1.9 8.8 ± 1.7
No. of previous ulcers* 3.7 ± 4.4 3.3 ± 4.0
Ulcer length* (mm) 14.3 ± 9.2 15.1 ± 12.0
Ulcer width* (mm) 11.3 ± 8.0 12.7 ± 11.9
*The values are given as the mean and the standard deviation. No significant difference (p > 0.05) between groups was found with use of
the t test between two independent means. †No significant difference (p > 0.05) between groups was found with use of chi-square analysis.
‡HbA1c = glycated hemoglobin.
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Secondary Outcome Measures
The range of dorsiflexion was measured with the subject
prone and with use of a standard goniometer by methods de-
scribed elsewhere25. The arms of the goniometer were aligned
parallel to the lateral aspect of the leg and the plantar aspect of
the foot. The reliability of this test in a similar population has
been established (intraclass correlation coefficient [formula
2,1]) = 0.96)25.
Concentric peak torque of the plantar flexor muscles
was measured as an indicator of muscle strength with use of
an isokinetic dynamometer (Kin-Com; Chattecx, Hixon, Ten-
nessee) according to methods with established reliability30,31.
Briefly, the subject was positioned on the dynamometer in the
supine position with the foot strapped to the ankle apparatus
and with the knee stabilized at 10° of flexion30. The testing
speed was 60°/sec, which is comparable with the angular ve-
locity of the ankle during the stance phase of walking31. Sub-
jects were allowed three, four, or five submaximal practice
contractions to become acquainted with the resistance and
speed of movement. The foot was then placed in a position of
maximum dorsiflexion, and the patient was instructed to push
as hard and as fast as possible through the full available range
of motion. Subjects were allowed to rest between each of the
three repetitions. The maximum peak torque of the three tri-
als was recorded as the peak torque.
Peak plantar pressures on the forefoot during barefoot
walking were measured with use of the EMED platform sys-
tem (Novel Electronics, Minneapolis, Minnesota) for both
feet. Data were collected at a sampling rate of 50 Hz as the
subject walked barefoot for at least three trials at a self-selected
speed across a walkway with the EMED pressure platform em-
bedded in the walkway. The location and magnitude of fore-
foot and hindfoot peak pressures for both feet were obtained
with use of a mean of the three trials to enhance the reliability
of the measures32. The subjects walked over the platform bare-
foot to determine the effects of surgery apart from the effects
of any foot-wear. Walking speed was recorded by measuring
the time required for the subject to walk a known distance.
Statistical Methods
A Fisher exact test was used to determine the significance of dif-
ferences between groups with respect to the number of ulcers
healed and ulcer recurrence rates. A t test was used to determine
the significance of differences in the time to healing. Kaplan-
Meier survival curves and Cox regression were used to evaluate
the data on reulceration for the two groups. A two (group) by
three (times of testing) repeated-measures analysis of variance
was used to determine differences in each of the secondary mea-
sures. Follow-up t tests with use of the error terms from the
analysis of variance were used for post hoc comparison on vari-
ables found to have a significant group-by-time interaction.
The alpha level for all analyses was set at 0.05.
Results
Primary Outcome Measures
Number of Ulcers Healed and Time to Healing
wenty-nine (88%) of the thirty-three ulcers in the total-
contact cast group and all thirty ulcers (100%) in the
Achilles tendon lengthening group healed after a mean dura-
tion of 40.8 ± 28.1 days and 57.5 ± 47.0 days, respectively.
There were no differences in the number of ulcers to heal (p =
0.12) or the time to healing (p = 0.14) between the groups.
Overall, 50% of the ulcers healed in forty-five days, and 85%
of the ulcers healed in sixty-three days.
Ulcer Recurrence Rates
Reulceration rates were significantly higher in the total-contact
cast group than in the Achilles tendon lengthening group. In the
first seven months of follow-up, sixteen (59%) of the twenty-
seven patients in the total-contact cast group who were available
T
TABLE II Foot Deformities and Comorbidities
Group Treated with 
Achilles Tendon Lengthening 
(n = 31)
Group Treated with 
Total-Contact Cast Alone 
(n = 33)
Foot deformities on involved side (no. of patients)
Transmetatarsal amputation 3 (10%) 2 (6%)
Toe and/or ray resection 9 (29%) 6 (18%)
Hammer or claw toe or toes 22 (71%) 24 (73%)
Hallux valgus 6 (19%) 7 (21%)
Comorbid conditions (no. of patients) 
Myocardial infarction 10 (32%) 9 (27%)
Cardiac artery bypass graft 6 (19%) 5 (15%)
Congestive heart failure 5 (16%) 6 (18%)
Hypertension 18 (58%) 18 (55%)
Retinopathy 10 (32%) 11 (33%)
Lower extremity revascularization 1 (3%) 3 (9%)
Renal failure 6 (19%) 4 (12%)
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for follow-up and four (15%) of the twenty-seven patients in
the Achilles tendon lengthening group who were available for
follow-up had recurrence of the plantar ulcers on the forefoot
(p = 0.001). The risk ratio for reulceration during the first seven
months after healing in the total-contact cast group compared
with the Achilles tendon lengthening group was 4.0 (95% confi-
dence interval, 1.8 to 8.9). At the time of the long-term follow-
up evaluation (a mean of 2.1 ± 0.7 years; range, 1.3 to 3.9 years
after the initial healing), twenty-one (81%) of the twenty-six
patients in the total-contact cast group and ten (38%) of the
twenty-six patients in the Achilles tendon lengthening group
had recurrence of the plantar ulcers on the forefoot (p = 0.002).
The risk ratio for reulceration during the 2.1 years after healing
in the total-contact cast group compared with the Achilles ten-
don lengthening group was 2.1 (95% confidence interval, 1.7 to
9.6). Patients in the total-contact cast group also had reulcer-
ation much sooner than did those in the Achilles tendon length-
ening group (the mean time to reulceration after healing was
131.2 ± 189.9 days and 431.0 ± 364.4 days, respectively; p =
0.03). The Kaplan-Meier survivor probability curve for each
group (Fig. 2) indicates the probability of being ulcer-free over
time. As illustrated in the curve, subjects were much more likely
to have an ulcer recurrence in the total-contact cast group than
in the Achilles tendon lengthening group, especially in the first
weeks after initial healing.
Secondary Outcome Measures (Table III)
The range of dorsiflexion for both groups was severely limited
prior to treatment (mean, –4.1° ± 7.0° in the Achilles tendon
lengthening group and –1.1° ± 7.0° in the total-contact cast
group, measured with knee extended). Dorsiflexion with the
knee extended and with the knee flexed increased 15.2° and
11.4°, respectively, following treatment with Achilles tendon
lengthening (postoperative compared with preoperative dorsi-
flexion, p < 0.001). Dorsiflexion remained essentially the same
seven months after treatment in the Achilles tendon lengthen-
ing group compared with the posttreatment value (p > 0.05).
Dorsiflexion in the total-contact cast group measured with the
knee extended or flexed changed ≤1.0° across the testing ses-
sions (p > 0.05). There were no differences in pretreatment
measurements between the groups with respect to any of the
secondary measures (p > 0.05).
Patients in the Achilles tendon lengthening group
showed a 32% decrease in peak torque (strength) of the plan-







After Treatment* P Value†
Range of dorsiflexion with knee in extension (deg)
Achilles tendon lengthening (n = 17) –4.1 ± 7.0 11.1 ± 4.1 10.8 ± 4.9 <0.001
Total-contact cast (n = 19) –1.1 ± 7.0 0.1 ± 3.9 –0.2 ± 5.2
Range of dorsiflexion with knee in flexion (deg)
Achilles tendon lengthening (n = 17) 3.0 ± 7.0 14.4 ± 4.5 13.9 ± 5.8 <0.001
Total-contact cast (n = 19) 6.5 ± 7.0 6.0 ± 4.8 6.7 ± 5.7
Peak torque (strength) of plantar flexors (Nm)
Achilles tendon lengthening (n = 15) 35.4 ± 13.2 23.9 ± 13.2 34.4 ± 15.5 <0.001
Total-contact cast (n = 14) 38.2 ± 13.1 42.0 ± 13.6 41.7 ± 16.3
Peak plantar pressure on forefoot (N/cm2)
Achilles tendon lengthening (n = 13) 89.24 ± 17.66 64.72 ± 30.67 88.78 ± 28.16 0.005
Total-contact cast (n = 11) 82.56 ± 23.70 86.52 ± 20.03 96.97 ± 16.81
Peak plantar pressure on hindfoot (N/cm2)
Achilles tendon lengthening (n = 12) 52.17 ± 22.89 70.06 ± 28.55 70.62 ± 28.05 0.018
Total-contact cast (n = 11) 51.77 ± 30.17 49.00 ± 23.74 55.77 ± 30.70
Peak plantar pressure on forefoot in uninvolved 
foot (N/cm2) 
Achilles tendon lengthening (n = 12) 87.86 ± 17.54 84.36 ± 23.64 86.54 ± 29.40 0.848
Total-contact cast (n = 11) 92.80 ± 15.40 91.52 ± 20.13 89.14 ± 18.05
Peak plantar pressure on hindfoot in uninvolved 
foot (N/cm2) 
Achilles tendon lengthening (n = 11) 55.15 ± 24.53 59.58 ± 19.39 60.82 ± 19.82 0.380
Total-contact cast (n = 11) 57.74 ± 31.77 55.09 ± 22.70 65.58 ± 31.37
*Values are given as the mean and the standard deviation. †Group × time interaction.
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tar flexor muscles following surgery (p < 0.004), but the peak
torque returned to the pretreatment level seven months after
surgery (p < 0.001). Patients in the total-contact cast group
showed no significant changes in peak torque of the plantar
flexors across the testing times (p > 0.05).
Patients in the Achilles tendon lengthening group showed
a 32% decrease in peak plantar pressures on the forefoot during
barefoot walking on the involved foot following surgery (p =
0.0002), but the peak plantar pressure returned to the pretreat-
ment level seven months after surgery (p = 0.0004). Patients in
the total-contact cast group showed no significant change in
peak plantar pressures on the forefoot after treatment, but there
was an increase in peak pressure on the forefoot from pretreat-
ment to the seven-month follow-up evaluation (mean, 83 ± 24
N/cm2 to 97 ± 17 N/cm2, p = 0.02). Peak plantar pressures on
the hindfoot for subjects in the Achilles tendon lengthening
group increased 34% after treatment (p = 0.007) and remained
at this increased level at the seven-month follow-up evaluation.
Peak plantar pressures on the hindfoot of the subjects in the
total-contact cast group did not change over time (p > 0.05).
Peak plantar pressures on the forefoot or the heel of the unin-
volved foot showed no significant differences between groups or
across time (p > 0.05). Walking speed, which may affect plantar
pressures, was not significantly different between the groups or
across the testing times.
Complications and Other Outcomes
Four (13%) of the thirty-one patients in the Achilles tendon
lengthening group had a heel ulcer develop following treat-
ment. Six (18%) of the thirty-three patients in the total-contact
cast group and four (13%) in the Achilles tendon lengthening
group had development of superficial abrasions as a result of
treatment with the cast; all healed once treatment with the cast
was complete. Three patients in the total-contact cast group
were intolerant of the cast, refused application of an additional
cast, and had immobilization of the foot and ankle with a re-
movable pressure-relief walking boot. No patient had a superfi-
cial infection develop from the Achilles tendon lengthening, but
one patient had a deep infection that required sharp débride-
ment and antibiotic therapy. Two patients (6.5%) in the Achilles
tendon lengthening group reported that they fell during the
time that the leg was immobilized in a total-contact cast, but
neither was injured. No patient required a major amputation
(transmetatarsal or transtibial amputation), but one patient in
the total-contact cast group required a toe amputation. Three
people (9%) in the total-contact cast group and three (10%) in
the Achilles tendon lengthening group died during the course of
the five-year study. One of the patients in the Achilles tendon
lengthening group died during the treatment phase. The re-
ported cause of death was a myocardial infarction.
Discussion
Primary Outcome Measures
he results support our primary hypothesis that Achilles
tendon lengthening helps to reduce ulcer recurrence rates
compared with treatment with a total-contact cast alone. Risk
reduction for ulcer recurrence after short-term (seven-month)
and long-term (2.1-year) follow-up in the Achilles tendon
lengthening group was 75% and 53%, respectively, compared
with the total-contact cast group. The time-period of greatest
risk for ulcer recurrence in the total-contact cast group was
the initial three weeks after treatment (Fig. 2). The patients in
the Achilles tendon lengthening group did not show this dra-
matic recurrence of ulceration.
We believe that a primary reason for the lower rate of
early recurrence in the Achilles tendon lengthening group
was that peak pressures on the forefoot were substantially re-
duced (27%) after the procedure. During barefoot walking,
the patients demonstrated plantar pressures on the forefoot
before and after the tenotomy (mean, 89 ± 18 N/cm2 to 65 ±
31 N/cm2, Table III) that were almost identical to those re-
ported by Armstrong et al. (mean, 86 ± 9 N/cm2 to 63 ± 13
N/cm2)7. The lower forefoot pressures may allow the ulcer to
heal more thoroughly. These forefoot pressures do not re-
main decreased, however. Within seven months after sur-
gery, the forefoot pressures returned to the pretreatment
level. Perhaps the slow increase of peak pressures on the
forefoot back to the baseline level allowed the initial ulcer to
heal and adapt to higher pressures more completely than if
high pressures were resumed immediately during walking af-
ter the initial healing.
Our data indicated that the peak pressures on the fore-
foot appeared to be related more to plantar flexor muscle
strength than to ankle dorsiflexion. Dorsiflexion increased
dramatically after the Achilles tendon lengthening and re-
mained increased for seven months. Plantar flexor muscle
strength decreased after surgery but returned to baseline
level in seven months, similar to the peak pressures on the
forefoot. Therefore, the peak pressures on the forefoot ap-
peared to be more related to the vigor of push-off generated
from the plantar flexor muscles than to the amount of ankle
dorsiflexion.
Patients in the total-contact cast group had a higher rate
of ulcer recurrence (59% at seven months and 81% at 2.1
years) than we had anticipated. Apelqvist et al. reported that
after one, three, and five years of observation, 34%, 61%, and
70%, respectively, of the patients with a previous ulcer had de-
velopment of a new foot ulcer15. Reiber et al. reported reulcer-
ation rates of only 14% to 17% over a two-year follow-up
period for patients with diabetes and a history of ulcer, but
none of the patients had severe foot deformity and only about
58% had loss of protective sensation33. We may have seen a
high rate of ulcer recurrence in our total-contact cast group
because this patient population had a mean of three or four
previous ulcers and all had peripheral neuropathy, loss of pro-
tective sensation, multiple comorbidities, and a severe limita-
tion of ankle dorsiflexion. These problems would place them
at high risk for recurrent skin breakdown.
The present study provides additional evidence that
treatment with a total-contact cast is a rapid and effective
method for healing plantar ulcers3,9-12, but an important limita-
tion of the method is the high rate of reulceration. Patients
T
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clearly require a slow progression from immobilization in a
total-contact cost to walking in appropriate foot-wear. Pa-
tients may benefit from a padded pressure-relief walker boot
as a transition from the total-contact cast to foot-wear. Al-
though the walker boot was used in the Achilles tendon
lengthening group after initial healing to help to provide sta-
bility secondary to the weak plantar flexor muscles, perhaps it
also provided extended protection to the plantar aspect of the
foot. This discrepancy in postoperative protocol between the
groups is a confounding factor in the interpretation of the re-
sults of this study. Additional research is needed to determine
the optimal progression and rehabilitation for patients who
transition from a total-contact cast to therapeutic foot-wear.
Secondary Outcome Measures
Ankle dorsiflexion increased an average of 15° after the Achil-
les tendon lengthening compared with an increase of 9° re-
ported by Armstrong et al.7 and 19° reported by Lin et al.6.
Each study described an end point in the range of dorsiflexion
of approximately 10°, which is the goal of surgery. Interest-
ingly, we found that the mean amount of dorsiflexion did not
change in the first seven months after surgery. Inclusion of an-
kle range-of-motion and strengthening exercises may have
helped to maintain this increased dorsiflexion over the seven-
month follow-up period.
The Achilles tendon lengthening resulted in a substantial
decrease (32%) in the plantar flexor strength after surgery and
immobilization, but strength returned to baseline after seven
months. There are few other quantitative data in the literature
describing the effects of surgery on the performance of the
plantar flexor muscles in the adult population, although post-
operative weakness of the plantar flexor muscles has been ob-
served in pediatric patients34,35. The finding of reduced plantar
flexor torque is consistent with computer simulations of the
procedure19,20. Despite the reduction in plantar flexor muscle
strength after surgery, strength returned to a baseline level after
seven months. The improvement in plantar flexor peak torque
may be related to the return to walking and the progressive re-
sistance exercise program. We do not know how compliant sub-
jects were with this home exercise program. Perhaps greater
improvements could be made with a more structured and/or
supervised exercise program. More research is needed to deter-
mine the ability of patients with diabetes and peripheral neu-
ropathy to increase muscle strength with use of a progressive
resistance exercise program.
Somewhat surprisingly, the total-contact cast group
showed no changes in the range of dorsiflexion or plantar
flexor muscle strength after immobilization. A number of
possible reasons may explain the maintenance of ankle range
of motion and strength in this group. First, the patients re-
mained weight-bearing throughout the duration of immobi-
lization. In addition, the negative effects of immobilization
may have been offset by the positive effects of ulcer-healing
and reduced edema in the leg. During initial testing, all sub-
jects had an open plantar ulcer. Although none of them com-
plained of pain during testing, they may have been reluctant
to perform maximally resisted plantar flexion. Furthermore,
the cast was changed every one to three weeks, and subjects
were encouraged to move the ankles. Although it was not
measured, reduction of edema during cast changes often was
apparent because the cast had become loose. The finding of
little change in the range of motion of the ankle joint follow-
ing treatment with a total-contact cast for the treatment of
neuropathic plantar ulcers is consistent with a report from
Diamond et al.36. A reduction in ankle range of motion and
strength does not appear to be a common complication of
treatment with a total-contact cast.
The Achilles tendon lengthening procedure resulted in a
34% increase in peak pressures on the heel, which likely was
related to the postoperative skin breakdown at the heel that
occurred in four subjects after the procedure. Clearly, Achilles
tendon lengthening causes an increase in ankle dorsiflexion
with reduced strength in the plantar flexor muscles to control
the motion, and weight is shifted from the forefoot to the heel
during standing and walking. Usually this shift in weight-
bearing is uneventful since the heel has a good fat pad for pro-
tection of skin breakdown, but four patients in the Achilles
tendon lengthening group had skin breakdown under the
heel. Of these four patients, none showed excessive increases
in ankle dorsiflexion (9° to 12°), and only one showed an un-
usually large increase (65%) in heel pressures. Patients should
be cautioned to watch for skin irritation of the heel following
Achilles tendon lengthening.
In conclusion, Achilles tendon lengthening should be
considered as an adjunct to treatment with a total-contact cast
in patients with a neuropathic plantar ulcer of the forefoot
and limited ankle dorsiflexion (≤5°) to decrease the rate of ul-
cer recurrence. 
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